abstract: BACKGROUND: We have previously described the hemostatic efficacy of a self-expanding @entity3 foam in lethal venous and @entity2 models. A number of critical translational questions remain, including prehospital diagnosis of @entity2 , use with @entity1 , effects on spontaneous respiration, the role of omentum, and presence of a laparotomy on foam properties. METHODS: In Experiment 1, diagnostic blood aspiration was attempted through a Veress needle before foam deployment during exsanguination (n = 53). In Experiment 2: a lethal @entity1 /diaphragmatic laceration was created followed by foam (n = 6) or resuscitation (n = 10). In Experiment 3, the foam was deployed in na  ve, spontaneously breathing animals (n = 7), and respiration was monitored. In Experiments 4 and 5, the foam was deployed above (n = 6) and below the omentum (n = 6) and in na  ve animals (n = 6). Intra-abdominal pressure and organ contact were assessed. RESULTS: In Experiment 1, blood was successfully aspirated from a Veress needle in 70% of lethal iliac artery injuries and 100% of lethal @entity1 . In Experiment 2, in the presence of a @entity1 , between 0 cc and 110 cc of foam was found within the pleural space. Foam treatment resulted in a survival benefit relative to the control group at 1 hour (p = 0.03). In Experiment 3, hypercarbia was observed: mean (SD) Pco2 was 48 (9.4) mm Hg at baseline and 65 (14) mm Hg at 60 minutes. In Experiment 4, abdominal omentum seemed to influence organ contact and transport in two foam deployments. In Experiment 5, there was no difference in intra-abdominal pressure following foam deployment in the absence of a midline laparotomy. CONCLUSION: In a series of large animal studies, we addressed key translational issues surrounding safe use of foam treatment. These additional data, from diagnosis to deployment, will guide @entity0 experiences with foam treatment for massive abdominal exsanguination where no other treatments are available.

title: Diagnosis and deployment of a self-expanding foam for abdominal exsanguination: Translational questions for XXXX use.

answer: @entity0


abstract: OBJECTIVE: The aim of this study was to examine the availability of diverse job accommodations (or flexible @entity3 ) and to describe their use among @entity0 with @entity2 ( @entity2 ), as well as to examine factors associated with the use of job accommodations. METHODS: A mail survey was sent to adult @entity2 @entity0 receiving care from a @entity2 clinic based in Toronto, Canada. The survey assessed demographic information, self-reported disease activity, work history, workplace activity limitations, job strain, and the availability and use of job accommodations. Standard multivariable linear regression analysis was used to examine factors associated with the use of job accommodations. RESULTS: We received 362 responses of 604 mailed surveys (60% response rate). @entity0 who were employed within the last 5 years, but who were not currently working, were less likely than currently employed @entity0 to report having had job accommodations available to them at their last place of employment. The use of job accommodations was reported by 70% of currently employed respondents and by 72% of those not currently employed. The most common job accommodation used was sick leave days. Factors positively associated with the use of job accommodations among those who were employed included higher levels of education, being diagnosed with @entity1 , at least 1 episode of short-term work disability, not belonging to a union, greater workplace activity limitations, and greater job strain. CONCLUSION: The use of job accommodations among @entity0 with @entity2 is common. Work context factors, such as workplace activity limitations and job strain, are the main factors associated with the use of job accommodations.

title: Job Accommodations Availability and Utilization Among XXXX With Lupus: An Examination of Workplace Activity Limitations and Work Context Factors.

answer: @entity0


abstract: A radioimmunoassay procedure to measure @entity5 (T3) in unextracted urine is described. One hundred microliter of T3 standards or samples were incubated with 100 microliter of T3 antiserum (1:40,000), 100 microliter of tracer 125I-T3 and 700 microliter of 0.05 M borate buffer, pH 8.6. Separation of free from bound antigen was achieved by dextran coated charcoal. The cross-reaction of L-T3 with @entity6 in this assay system was less than 0.2%. Dilution of high T3 urine was parallel to the standard curve. Recovery was 101 +/- 8%. Coefficients of variation were 3-8% within each assay and 13% between assays. Euthyroid subjects excreted 0.81 +/- 0.39 microgram (mean +/- S.D.) in 24 hr. Similar values were obtained in pregnant @entity0 , @entity7 @entity0 with @entity8 , and a @entity0 with @entity9 . Excretion of urinary T3 was high (7.48 +/- 3.32 microgram/24 h) in @entity0 with @entity4 , and low (0.14 +/- 0.15 microgram/24 hr) in @entity0 with @entity3 . Urinary T3 excretion was almost undetectable in @entity1 . Positive correlations were found between urinary T3 and serum total T3 (r = 0.89) and especially serum free T3 (r - 0.97). A positive correlation was also found between urinary T3 and @entity2 clearance (r = 0.63). Mean urinary clearance of T3(CT3=Urinary T3 excretion/serum free T3 was 166 ml/min and was significantly higher than their mean @entity2 clearance (110 ml/min). The measurement of T3 in urine is reliable and easy to perform, and may allow a new approach to the understanding of thyroid hormone metabolism.

title: Measurement of XXXX in urine.

answer: @entity5


abstract: @entity13 is a @entity8 consisting of a facial @entity12 associated with @entity11 and a @entity9 . It is a rare @entity14 that occurs sporadically, is not inherited, and is caused by a somatic mosaic mutation in @entity15 . In @entity0 with @entity13 , brain involvement typically presents in infancy with @entity4 , @entity2 , and @entity2 -like episodes, and a range of @entity1 . Standard treatment includes laser therapy for the birthmark, control of @entity6 through eyedrops or surgery, and the use of anticonvulsants. Increasingly low-dose @entity3 is offered. Treatment with @entity7 has been tried generally without the dramatic results seen in @entity10 . Treatment with an anticonvulsant or low-dose @entity3 or both before the onset of @entity4 is an option. Surgical resection may be offered to those whose @entity4 are medically refractory. Endocrine, medical rehabilitation and cognitive comorbidities are important to manage. In the future, new therapeutic options are likely to be offered stemming from preclinical studies and small pilot clinical trials currently ongoing. Discovery of the causative somatic mosaic mutation suggests new insights into the pathophysiology of this @entity5 , and potential novel treatment strategies for future study. The mutation results in constitutive overactivation of the Ras-Raf-MEK-ERK and the HIPPO-YAP pathways and inhibitors of these pathways may in the future prove useful in the treatment of @entity13 .

title: Current Therapeutic Options in XXXX .

answer: @entity13


abstract: OBJECTIVES: Exercise can improve motor function in @entity0 with @entity1 but @entity2 reduces the motivation to participate in regular exercise. The aim of this study was to develop a novel Enhanced Exercise Therapy program that uses manual-driven guided exercise and peer-facilitated psychoeducation for individuals with @entity1 and @entity2 . DESIGN: 24 week randomized controlled design. METHODS: Thirty individuals were randomized to Enhanced Exercise Therapy or self-guided therapy, and evaluated at baseline, 12-weeks and at 24-weeks. Enhanced Exercise Therapy included group exercise and group psychoeducation for 12 weeks. Between 13 and 24 weeks, individuals had access to the fitness facility but group sessions were not held. Self-guided therapy included written guidelines for a self-paced exercise program and psychoeducation. Primary outcome measures included the number of exercise sessions and International Physical Activity Questionnaire score. Secondary measures included resting heart rate, supine blood pressure, estimated VO2max and incidence of @entity3 . RESULTS: Twenty four individuals completed the study (80% retention) and both groups attended similar number of exercise sessions. There were no significant changes in cardiovascular fitness measures but there was a significant increase in the amount of physical activity in the Enhanced Exercise Therapy group and a decrease in the self-guided therapy group during the post-intervention period. CONCLUSIONS: Enhanced Exercise Therapy appears to promote engagement in an exercise program and more physical activity, even after group sessions were concluded in individuals with @entity1 and @entity2 .

title: Enhanced Exercise Therapy in XXXX : A comparative effectiveness trial.

answer: @entity1


abstract: UNASSIGNED: Guidelines in the United States recommend consideration of testing for mutations in the @entity3 and @entity2 genes for @entity1 diagnosed with @entity0 under age 45. Identification of mutations among survivors has implications for secondary prevention and familial risk reduction. Although only 10  % of @entity0 are diagnosed under age 45, there are approximately 2.8  million @entity0 survivors in the United States, such that the young survivor population likely numbers in the hundreds of thousands. However, little is known about genetic testing rates in this population. We assessed trends in @entity4 testing among @entity0 survivors who were under age 45 at diagnosis and were treated from 2005 to 2012. Using insurance claims from a national database (MarketScan), we identified incident @entity0 cases among (1) @entity1 aged  <=40 and (2) @entity1 aged 41-45. We measured @entity3 /2 testing using Kaplan-Meier analysis and Cox proportional hazards models. Among 26,985 @entity1 analyzed, @entity3 /2 testing rates increased with each year of diagnosis from 2005 to 2012 (P  <  0.001). However, among @entity1 treated in earlier years, testing rates did not approach those of @entity1 treated later, even after extended follow-up (median time from surgery to testing among @entity1 treated in 2005, not reached; median time to testing among @entity1 treated in 2012, 0.2  months for @entity1 aged  <=40 and 1.0  month for @entity1 aged 41-45). @entity1 aged 41-45 had lower rates than @entity1 aged  <=40 throughout the analysis period (P  <  0.001 for each year). @entity4 testing rates among young @entity1 with incident @entity0 increased substantially in the last decade. However, most survivors treated in earlier years have never been tested. Our results demonstrate a need to better incorporate genetic counseling into survivorship and primary care for this population.

title: Rates of @entity4 mutation testing among young survivors of XXXX .

answer: @entity0


abstract: UNASSIGNED: Guidelines in the United States recommend consideration of testing for mutations in the @entity3 and @entity2 genes for @entity1 diagnosed with @entity0 under age 45. Identification of mutations among survivors has implications for secondary prevention and familial risk reduction. Although only 10  % of @entity0 are diagnosed under age 45, there are approximately 2.8  million @entity0 survivors in the United States, such that the young survivor population likely numbers in the hundreds of thousands. However, little is known about genetic testing rates in this population. We assessed trends in @entity4 testing among @entity0 survivors who were under age 45 at diagnosis and were treated from 2005 to 2012. Using insurance claims from a national database (MarketScan), we identified incident @entity0 cases among (1) @entity1 aged  <=40 and (2) @entity1 aged 41-45. We measured @entity3 /2 testing using Kaplan-Meier analysis and Cox proportional hazards models. Among 26,985 @entity1 analyzed, @entity3 /2 testing rates increased with each year of diagnosis from 2005 to 2012 (P  <  0.001). However, among @entity1 treated in earlier years, testing rates did not approach those of @entity1 treated later, even after extended follow-up (median time from surgery to testing among @entity1 treated in 2005, not reached; median time to testing among @entity1 treated in 2012, 0.2  months for @entity1 aged  <=40 and 1.0  month for @entity1 aged 41-45). @entity1 aged 41-45 had lower rates than @entity1 aged  <=40 throughout the analysis period (P  <  0.001 for each year). @entity4 testing rates among young @entity1 with incident @entity0 increased substantially in the last decade. However, most survivors treated in earlier years have never been tested. Our results demonstrate a need to better incorporate genetic counseling into survivorship and primary care for this population.

title: Rates of XXXX mutation testing among young survivors of @entity0 .

answer: @entity4


abstract: @entity8 ( @entity8 ), the classical animal model for experimental @entity5 , resembles @entity0 @entity4 in several aspects. However, the most widely used method of inducing @entity8 utilizes Freund's adjuvants, which can skew the elicited immune responses and also pose @entity2 problems. This unit describes a new method of inducing @entity8 using a well defined stimuli-responsive synthetic polymer, @entity7 -based adjuvant, mixed with the joint cartilage protein collagen type II (CII). @entity7 as an adjuvant is biodegradable and biocompatible, and does not skew immune responses. Thus, it is helpful in the development of @entity5 models for studying antigen and tissue -specific autoimmune responses in an unbiased manner. This model is valuable for analyzing disease pathways, positional identification of genes regulating @entity5 , validation of existing therapies, and exploring new therapeutic targets. Furthermore, this newly developed @entity7 adjuvant allows investigation of disease induction using specific autoantigens in several @entity6 independently of toll-like receptors, as well as optimization of vaccine delivery systems for @entity3 . Curr. Protoc. @entity1 Biol. 4:11-24    2014 by John Wiley _ Sons, Inc.

title: Synthetic polymer as an adjuvant in collagen-induced XXXX .

answer: @entity5


abstract: UNASSIGNED: The objectives of this study were to investigate the effects of feeding @entity3 naturally contaminated with Fusarium mycotoxins on growth performance, @entity0 , and digestibility of dry matter, organic matter, and crude protein of gilts and the recovery of gilts fed normal diets immediately after the exposure to contaminated diets by measuring growth performance and @entity0 . In Exp. 1, four diets were prepared to contain 0%, 15%, 30%, or 45% contaminated @entity3 containing 25.7 mg/kg @entity5 and 26.0  g/kg @entity6 . Sixteen gilts with an initial body weight (BW) of 33.3 kg (standard deviation = 3.0) were individually housed in a metabolism crate and assigned to 4 diets with 4 replicates in a randomized complete block design based on BW. During the 14-d feeding trial, individual BW and feed consumption were measured weekly and the vertical and horizontal lengths of vulva were measured every 3 d. From d 10, feces were collected by the maker-to-marker method for 4 d. Blood samples were collected on d 14. During the overall period, the average daily gain, average daily feed intake, and gain:feed of @entity2 linearly decreased (p<0.01) as the dietary concentration of contaminated @entity3 increased. However, the digestibility of crude protein was linearly increased (p = 0.011) with the increasing amounts of contaminated @entity3 . Increasing dietary Fusarium mycotoxin concentrations did not influence vulva size, blood characteristic as well as immunoglobulin level of @entity2 . In the Exp. 2, a @entity4 - @entity1 meal-based diet was formulated as a recovery diet. @entity2 were fed the recovery diet immediately after completion of the Exp. 1. During the 14-d of recovery period, the individual BW and feed consumption were measured weekly and the vertical and horizontal length of vulva were measured every 3 d from d 0. On d 7, the feed intake of @entity2 previously fed contaminated diets already reached that of @entity2 fed a diet with 0% contaminated @entity3 and no significant difference in growth performance among treatments was observed during d 7 to 14 of the recovery period. In conclusion, increasing levels of mycotoxins in diets linearly decreased the growth performance of @entity2 , and these damages can be recovered in 7 d after the diet was replaced with a normal diet. The vulva size, blood characteristic, immune responses were not affected by increasing level of contaminated @entity3 in the diets fed to @entity2 .

title: Effects of Feeding XXXX Naturally Contaminated with Fusarium Mycotoxins on Growth Performance, Nutrient Digestibility, and Blood Chemistry of Gilts and Growth Recoveries by Feeding a Non-contaminated Diet.

answer: @entity3


abstract: We have measured puff by puff the effect of smoking three brands of cigarettes with different composition on airways resistance (Raw) thoracic gas volume (TGV) and the maximal expiratory flow volume (MEFV) curve. Raw increased significantly with all three brands of cigarettes after one puff. The maximum effect was reached after three puffs. Instantaneous flow at 50% of vital capacity (FEF50) decreased significantly with cigarettes high in @entity1 content, but not so after smoking a low @entity1 (0.31 mg) cigarette. Instantaneous flow at 75% of vital capacity out (FEF75) increased significantly 30 min after the low @entity1 cigarette was smoked. A deep inspiration prior to Raw determination reduced by approximately one third the bronchoconstrictor effect of cigarette smoke. All effects were reversible within 30 min, except the delayed effect of the low @entity1 cigarette on the FEF75. We conclude that the probable site of action of @entity0 smoke is in the large and central airways. The bronchoconstrictor effect rapidly reaches a plateau. A delayed bronchodilation of the small airways observed after smoking the low @entity1 cigarette might represent a response usually masked by other long-acting components in smoke. We suggest that the airway response to @entity0 smoke is complex and probably a result of several components present in smoke which still have to be identified.

title: Airways response to inhaled XXXX smoke: time course, dose dependence and effect of volume history.

answer: @entity0


abstract: Measuring forces applied by multi-cellular organisms is valuable in investigating biomechanics of their locomotion. Several technologies have been developed to measure such forces, for example, strain gauges, micro-machined sensors, and calibrated cantilevers. We introduce an innovative combination of techniques as a high throughput screening tool to assess forces applied by multiple genetic model organisms. First, we fabricated colored @entity3 ( @entity4 ) micropillars where the color enhances contrast making it easier to detect and track pillar displacement driven by the organism. Second, we developed a semi-automated graphical user interface to analyze the images for pillar displacement, thus reducing the analysis time for each animal to minutes. The addition of color reduced the Young's modulus of @entity4 . Therefore, the dye- @entity4 composite was characterized using Yeoh's hyperelastic model and the pillars were calibrated using a @entity2 based force sensor. We used our device to measure forces exerted by wild type and mutant @entity1 moving on an agarose surface. Wild type @entity1 exert an average force of    1    N on an individual pillar and a total average force of    7.68    N. We show that the middle of @entity1 exerts more force than its extremities. We find that @entity1 mutants with defective body wall muscles apply significantly lower force on individual pillars, while mutants defective in sensing externally applied mechanical forces still apply the same average force per pillar compared to wild type animals. Average forces applied per pillar are independent of the length, diameter, or cuticle stiffness of the animal. We also used the device to measure, for the first time, forces applied by @entity0 larvae. Peristaltic waves occurred at 0.4   Hz applying an average force of    1.58    N on a single pillar. Our colored microfluidic device along with its displacement tracking software allows us to measure forces applied by multiple model organisms that crawl or slither to travel through their environment.

title: Colored XXXX micropillar arrays for high throughput measurements of forces applied by genetic model organisms.

answer: @entity3


abstract: Relaxin hormone secreted into the circulation during pregnancy was discovered through its effects on pubic symphysis relaxation and parturition. Genetic inactivation of the relaxin gene or its cognate @entity3 ( @entity3 ) in @entity0 caused failure of parturition and mammary nipple enlargement, as well as increased collagen fiber density in the cervix and vagina. However, the relaxin effect on discrete cells and tissues has yet to be determined. Using @entity0 with a knockin LacZ reporter in the @entity3 allele, we showed strong expression of this gene in vaginal and cervical stromal cells, as well as pubic ligament cells. We produced a floxed @entity3 allele that was used in combination with the @entity1 -cre transgene to generate @entity0 with a smooth muscle-specific gene knockout. In pregnant females, the @entity2 reporter activated by @entity1 -cre was detected in smooth muscle cells of the cervix, vagina, uterine artery, and in cells of the pubic symphysis. In late pregnant females with conditional gene ablation, the length of pubic symphysis was significantly reduced compared with wild-type or heterozygous @entity3 (+/-) females. Denser collagen content was revealed by Masson trichrome staining in reproductive tract organs, uterine artery, and pubic symphysis. The cervical and vaginal epithelium was less developed than in heterozygous or wild-type females, although nipple size was normal and the dams were able to nurse their pups. In summary, our data indicate that relaxin/ @entity3 signaling in smooth muscle cells is important for normal collagen turnover and relaxation of the pubic symphysis during pregnancy.

title: Conditional deletion of the relaxin receptor gene in cells of smooth muscle lineage affects lower reproductive tract in pregnant XXXX .

answer: @entity0


abstract: UNASSIGNED: The biological responses of @entity2 ( @entity3 ) nanoparticles (NPs) and nanowires (NWs) in cultured fibroblasts (L929) and macrophages (RAW264) were evaluated from their cytotoxicities and micromorphologic properties. Cultured cells were exposed to @entity3 NPs (13 nm diameter) and @entity3 NWs (2-6 * 200-400 nm). @entity1 and genotoxicity were examined by immunostaining with fluorescence microscopy, and nanomaterial localization was studied by using scanning electron microscopy and transmission electron microscopy. The NPs were cytotoxic and genotoxic, whereas the NWs were not. The scanning electron microscopy images showed that the NPs aggregate more on the cell surface than do the NWs. The transmission electron microscopy images showed that the NPs were internalized into the vesicle and nuclei, for both cell types. In contrast, numerous solid NWs were observed as large aggregates in vesicles, but not in nuclei. @entity0 was confirmed by measuring cell viability and by immunostaining for NPs. The chemical changes induced by the NPs in the vesicles or cells may cause cell damage because of their large surface area per volume. The extent of NW entrapment was not sufficient to lower the viability of either cell type.    2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 104B: 241-252, 2016.

title: Investigation of the cytotoxicity of XXXX nanoparticles and nanowires and their localization in L929 fibroblasts and RAW264 macrophages.

answer: @entity2


abstract: Impedance reduction with a continuous infusion of @entity2 was evaluated in 20 @entity0 following cardiopulmonary bypass. @entity0 were selected for therapy when the cardiac index (CI) was less than 2.2 L/m2/min, when the systemic vascular resistance index (SVRI) was greater than 2,500 dyne sec cm-5, or when both conditions were present. No other vasoactive or cardiotonic drugs were used intraoperatively or postoperatively. Responses were measured at 15, 30, 60, 120, 180, and 240 minutes and compared with control measurements. Significant responses appeared by 15 minutes in the mean arterial pressure, CI, and SVRI, which were maximal by 2 hours. At 4 hours, the SVRI was 1,520 +/- 276 dyne sec cm-5 (control, 3,235 +/- 222) and pulmonary vascular resistance index, 365 +/- 102 dyne sec cm-5 (control, 592 +/- 71). The CI was 3.20 +/- 0.29 L/m2/min (control, 1.96 +/- 0.16) and mean arterial pressure, 75 +/- 2.3 mm Hg (control, 92 +/- 2.4). Left @entity1 diastolic, and right atrial pressures increased from control but not significantly: 11.4 +/- 0.8 to 13.3 +/- 1.2 mm Hg, 13.6 +/- 1.6 to 17.2 +/- 1.5 mm Hg, and 6 +/- 1.6 to 9.4 +/- 1.7 mm Hg, respectively. In 16 @entity0 , @entity2 was continued for 24 hours and in 11, the transition to oral therapy was made. @entity2 by infusion effectively reduces after load, avoids the fluctuations of bolus therapy, and allows the transition to oral therapy if needed.

title: Continuous XXXX infusion for afterload reduction.

answer: @entity2


abstract: PURPOSE: The purpose of the present study was to determine liver, pancreas, kidney, and vertebral fat deposition in @entity5 @entity0 by proton density fat fraction (PDFF) using magnetic resonance imaging (MRI) and to evaluate the relationships among them. METHODS: A total of 41 biopsy-proven @entity5 @entity0 underwent MRI-PDFF with IDEAL-IQ. MRI protocol included T1-independent volumetric multi-echo gradient-echo imaging with T2* correction and spectral fat modeling. The MR examinations were performed on a 1.5 HDx MRI system. MRI-PDFF measurements were obtained from liver, @entity2 . Liver biopsy specimens were retrieved from the archives and evaluated by one pathologist according to NASH CRN. RESULTS: The median age of the @entity0 was 47  years. The median interval between liver biopsy and MRI examination was 16  days. Mean liver, @entity2 , T12 and L1 vertebral body MRI-PDFFs were 18.7%, 5.7%, 1.7%, 51%, 43.2%, and 43.5%, respectively. No correlation between either liver MRI-PDFF or histological steatosis, and other organ MRI-PDFFs was observed. A good correlation between @entity4 was observed. @entity1 @entity0 had higher average pancreas MRI-PDFF compared to non- @entity1 (12.2%, vs., 4.8%; P  =  0.028). CONCLUSIONS: Pancreas and vertebral body MRI-PDFF is well correlated in @entity5 @entity0 and both of them are higher in @entity1 @entity0 which may explain @entity3 in @entity1 . MRI-PDFF can be used to demonstrate fat fractions of different organs and tissues and to understand fat metabolism.

title: Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in XXXX .

answer: @entity5


abstract: @entity8 ( @entity8 ) can show variant histological patterns in the gastrointestinal system. We present a case of an 11-year-old @entity0 who has been followed up with a diagnosis of @entity8 since he was 6   months old. He presented with @entity4 and @entity2 . Colonoscopic biopsy showed crypt destructive @entity6 , severe decrease and focal absence of plasma cells. Three months later he suffered from @entity4 . Macroscopic examination of small intestinal resection material revealed multiple perforation areas, @entity5 . Histopathology showed mild-moderate @entity7 with @entity9 , @entity3 , decrease in plasma cells and loss of primary follicles in lymph nodes. Histopathological findings were consistent with @entity1 ( @entity1 )-like @entity8 . Although in 6-10% of @entity0 with @entity8 an @entity1 -like presentation is observed, this highly aggressive form is rarely seen. We present this case because of its extraordinary presentation displaying perforating @entity7 .

title: Inflammatory bowel disease-like colitis pathology in a XXXX with common variable immune deficiency.

answer: @entity0


abstract: Three cases of peritoneal @entity5 are reported with guidelines for the diagnosis of this type of complication. The authors point out the value of the following signs: 1--increase of ventricular pressure with worsening of the clinical picture; 2--localized @entity1 in the abdomen; 3--difficulty to depress the capsule; 4--occurrence of subcutaneous collection of @entity4 around the pathway of the catheter. In some occasions it is possible to palpate the mass of the pseudocyst. The presence of subcutaneous collection of @entity4 around the pathway of the catheter is an important warning sign of peritoneal pseudocyst and must be differentiated from that originated by the disconnection between the capsule and the catheter. In this condition however, the accumulation of liquid begins in the cervical region. Also in this case the capsule @entity2 easily. The most precise diagnosis is achieved by X-Ray. The authors describe a method that consists in introducing a needle through the capsule and injecting 8cc of Dimer-X contrast. The catheter and the cavity of pseudo-cyst appear contrasted in the X-Ray film, establishing the definitive diagnosis. The authors discuss the physiopathology of @entity4 accumulation; once the pseudocyst is formed, the intracranial pressure increases, and the fontanelle bulges, this leads to repeated pumping by the relatives and subsequent rising of pressure within the pseudo-cyst. At this point the @entity0 refers @entity1 at the location of the pseudo-cyst and the @entity4 tends to lead around catheter. In babies the @entity3 leads to crying, thus increasing once more the intra-cystic pressure which favors the leakage of @entity4 from the pseudo-cyst around the catheter.

title: [Peritoneal XXXX as a complication of cerebrospinal fluid shunt. Report of 3 cases and contribution for diagnosis].

answer: @entity5


abstract: Young ducklings were inoculated intravenously (IV) twice with either @entity1 or @entity0 red blood cells (CRBC, SRBC). Breeder @entity2 were inoculated IV twice with an increased dose of CRBC. Sera of these actively immunized @entity2 and sera of day-old ducklings from the CRBC-inoculated breeder @entity2 were tested for @entity5 in direct-hemagglutination ( @entity3 ) tests. The young ducklings and the breeders responded with very low @entity3 titers to CRBC and SRBC. Although ducklings inoculated with CRBC developed a true secondary response to a second CRBC inoculation, ducklings inoculated with SRBC failed to develop elevated titers after a second of SRBC inoculation. Half the breeders failed to develop higher titers to a second CRBC inoculation. Sera from the majority of day-old ducklings hatched from eggs laid after one inoculation of the breeders had no or only minimal @entity3 activity. Sera of ducklings hatched from eggs laid after the second inoculation had somewhat higher @entity3 titers, and in greater proportion. Still, many of those duckling sera had no or minimal @entity3 titers. Results with Sephadex G-200 fractions indicated that hemagglutinins after one inoculation resided primarily in @entity2 immunoglobulin M (DIgM). Sera of @entity2 inoculated twice with CRBC had hemagglutinating activity in DIgG, too. Hemagglutinating activity was demonstrated in both @entity4 -sensitive (DIgM) and -resistant (DIgG) antibodies. The conspicuously low titers in all @entity3 -positive sera agree with results of previous studies, suggesting that DIg's are deficient in immunological reactions requiring functional bivalency.

title: Immune response of the XXXX to particulate (red blood cell) antigens.

answer: @entity2


abstract: Over a two-year period, 44 @entity0 had an eosinophil count above the 97th centile. Thirteen of these 44 had @entity1 presenting within six months of the onset of symptoms. Microfilariasis was the most likely cause of the raised total eosinophil in these 13 @entity0 . In all, the raised eosinophil count we returned to normal by the use of @entity5 (Banocide). Eleven of the 13 were followed up and eight of them (73%) developed clinical features of @entity1 and @entity2 . The mean duration of follow-up was two years. Limited cardiac catheterisation studies in six of the @entity0 showed evidence of constriction or of @entity2 . The clinical features of these eight @entity0 were indistinguishable from those found in chronic @entity6 . This disease was further suggested by recurrent @entity3 in one, and a large pericardial effusion in another; and it was also present in the one @entity0 to come to necropsy. Thus, microfilaria-induced @entity4 , when high, is frequently associated with @entity1 which appears to be chronic @entity6 many months after the @entity4 has returned to normal.

title: Relation of severe @entity4 and microfilariasis to chronic XXXX .

answer: @entity6


abstract: Over a two-year period, 44 @entity0 had an eosinophil count above the 97th centile. Thirteen of these 44 had @entity1 presenting within six months of the onset of symptoms. Microfilariasis was the most likely cause of the raised total eosinophil in these 13 @entity0 . In all, the raised eosinophil count we returned to normal by the use of @entity5 (Banocide). Eleven of the 13 were followed up and eight of them (73%) developed clinical features of @entity1 and @entity2 . The mean duration of follow-up was two years. Limited cardiac catheterisation studies in six of the @entity0 showed evidence of constriction or of @entity2 . The clinical features of these eight @entity0 were indistinguishable from those found in chronic @entity6 . This disease was further suggested by recurrent @entity3 in one, and a large pericardial effusion in another; and it was also present in the one @entity0 to come to necropsy. Thus, microfilaria-induced @entity4 , when high, is frequently associated with @entity1 which appears to be chronic @entity6 many months after the @entity4 has returned to normal.

title: Relation of severe XXXX and microfilariasis to chronic @entity6 .

answer: @entity4


abstract: BACKGROUND/AIMS: The management for the obstructive left sided @entity2 is still controversial. METHODOLOGY: A retrospective study was performed on 249 consecutive @entity0 who underwent surgical intervention for left sided @entity2 in our hospital. Among 36 @entity0 who had @entity3 , 25 @entity0 received @entity1 resection while the rest of the @entity0 received palliative stoma creation. Clinical characteristics and outcome following @entity1 resection was compared between @entity0 with and without @entity3 . RESULTS: Prior to @entity1 resection, all @entity0 received colonic decompression. Flowingly, 20 @entity0 received staged surgeries and five @entity0 underwent one stage surgery, with three of the latter requiring reoperation due to @entity4 . The five-year overall survival rate for @entity0 following @entity1 resection was 75.5 % and 69.1 % for those with and without @entity3 respectively. Log-rank test showed no significant difference in overall survival between the two groups (p = 0.91). CONCLUSIONS: Onestage surgery for @entity0 with obstructive @entity2 in our hospital was associated with frequent @entity4 . @entity3 itself may not be a poor prognostic factor when decompression preceded surgical resection.

title: Staged surgery after colonic decompression may be safer for the treatment of obstructive left-sided XXXX in a non-specialized hospital.

answer: @entity2


abstract: Recruitment of innate immune effector cells into sites of @entity2 is a critical component of resistance to pathogen @entity2 . Using a model of intradermal footpad injection of @entity4 , we observed that @entity1 as measured by footpad thickness and neutrophil recruitment occurred independent of adoptive immunity but was significantly reduced in MyD88(-/-) and @entity3 (-/-) @entity0 . Unexpectedly, huLangerin-DTA @entity0 (  LC) that lack Langerhans cells (LC) developed @entity1 and expressed higher amounts of @entity3 , suggesting a suppressive role for LC. Increased @entity1 also occurred in @entity5 (-/-)   LC @entity0 but was reversed by Ab-mediated ablation of NK cells. @entity6 (+) @entity7 (+) NK cells are a liver-resident subset that can mediate inflammatory skin responses. We found that exaggerated @entity1 was absent in   LC * @entity6 (-/-) @entity0 . Moreover, the exaggerated response in   LC @entity0 could be adoptively transferred with liver @entity7 (+) NK cells. Finally, @entity7 (+) NK cells in   LC but not control @entity0 were recruited to the skin, and inhibition of their recruitment prevented the exaggerated response. Thus, in the absence of LC, @entity7 (+) liver NK cells display an inappropriately proinflammatory phenotype that results in @entity1 . These data reveal a novel function for LC in the regulation of this recently described subset of skin tropic NK cells.

title: Langerhans Cells Suppress XXXX + NK Cell-Mediated @entity1 .

answer: @entity7


abstract: Recruitment of innate immune effector cells into sites of @entity2 is a critical component of resistance to pathogen @entity2 . Using a model of intradermal footpad injection of @entity4 , we observed that @entity1 as measured by footpad thickness and neutrophil recruitment occurred independent of adoptive immunity but was significantly reduced in MyD88(-/-) and @entity3 (-/-) @entity0 . Unexpectedly, huLangerin-DTA @entity0 (  LC) that lack Langerhans cells (LC) developed @entity1 and expressed higher amounts of @entity3 , suggesting a suppressive role for LC. Increased @entity1 also occurred in @entity5 (-/-)   LC @entity0 but was reversed by Ab-mediated ablation of NK cells. @entity6 (+) @entity7 (+) NK cells are a liver-resident subset that can mediate inflammatory skin responses. We found that exaggerated @entity1 was absent in   LC * @entity6 (-/-) @entity0 . Moreover, the exaggerated response in   LC @entity0 could be adoptively transferred with liver @entity7 (+) NK cells. Finally, @entity7 (+) NK cells in   LC but not control @entity0 were recruited to the skin, and inhibition of their recruitment prevented the exaggerated response. Thus, in the absence of LC, @entity7 (+) liver NK cells display an inappropriately proinflammatory phenotype that results in @entity1 . These data reveal a novel function for LC in the regulation of this recently described subset of skin tropic NK cells.

title: Langerhans Cells Suppress @entity7 + NK Cell-Mediated XXXX .

answer: @entity1


abstract: During embryonic development, oral ectoderm differentiates into the adenohypophysis, dental epithelia, salivary glands, and nasal pit. Few reports exist concerning the induction of oral ectoderm from embryonic stem (ES) cells. Generally, any lot differences in @entity1 ( @entity1 ) and serum replacer may affect the induction of ES cell-differentiation. Using a previously established culture strategy for differentiation, the proportion of cell aggregates containing @entity3 + oral ectoderm varied widely between 9-36% when several different lots of @entity1 or serum replacer were used. We therefore tried to enhance the differentiation method. We found that @entity2 and fibroblast growth factor (FGF) treatments improved oral ectoderm induction. Such treatment also improved the differentiation of oral ectoderm into the adenohypophysis. Furthermore, increased @entity2 treatment induced dental epithelium and mesenchyme. Such differentiation suggests that the @entity3 + layer displays similar properties to oral ectoderm, as found in vivo. Differentiation of ES cells into oral ectoderm using different lots of @entity1 and serum replacer increased 78-90% after treatment with @entity2 and FGF. In summary, we have established a robust strategy for the induction of oral ectoderm differentiation from @entity0 ES cells.

title: XXXX and FGF strongly induce differentiation of @entity0 ES cells into oral ectoderm.

answer: @entity2


abstract: During embryonic development, oral ectoderm differentiates into the adenohypophysis, dental epithelia, salivary glands, and nasal pit. Few reports exist concerning the induction of oral ectoderm from embryonic stem (ES) cells. Generally, any lot differences in @entity1 ( @entity1 ) and serum replacer may affect the induction of ES cell-differentiation. Using a previously established culture strategy for differentiation, the proportion of cell aggregates containing @entity3 + oral ectoderm varied widely between 9-36% when several different lots of @entity1 or serum replacer were used. We therefore tried to enhance the differentiation method. We found that @entity2 and fibroblast growth factor (FGF) treatments improved oral ectoderm induction. Such treatment also improved the differentiation of oral ectoderm into the adenohypophysis. Furthermore, increased @entity2 treatment induced dental epithelium and mesenchyme. Such differentiation suggests that the @entity3 + layer displays similar properties to oral ectoderm, as found in vivo. Differentiation of ES cells into oral ectoderm using different lots of @entity1 and serum replacer increased 78-90% after treatment with @entity2 and FGF. In summary, we have established a robust strategy for the induction of oral ectoderm differentiation from @entity0 ES cells.

title: @entity2 and FGF strongly induce differentiation of XXXX ES cells into oral ectoderm.

answer: @entity0


abstract: Leishmania is a digenetic protozoan parasite causing @entity1 in @entity0 . The different clinical forms of @entity1 are caused by more than twenty species of Leishmania that are transmitted by nearly thirty species of phlebotomine sand flies. Pentavalent antimonials (such as Pentostam or Glucantime) are the first line drugs for treating @entity1 . Recent studies suggest that pentavalent antimony (Sb(V)) acts as a pro-drug, which is converted to the more active trivalent form (Sb(III)). However, sensitivity to trivalent antimony varies among different @entity5 . In general, @entity5 causing @entity4 ( @entity4 ) are more sensitive to Sb(III) than the species responsible for @entity2 ( @entity2 ). Leishmania aquaglyceroporin ( @entity3 ) facilitates the adventitious passage of antimonite down a concentration gradient. In this study, we show that @entity5 causing @entity4 accumulate more antimonite, and therefore exhibit higher sensitivity to antimonials, than the species responsible for @entity2 . This species-specific differential sensitivity to antimonite is directly proportional to the expression levels of @entity3 mRNA. We show that the stability of @entity3 mRNA in different @entity5 is regulated by their respective 3'-untranslated regions. The differential regulation of @entity3 mRNA explains the distinct antimonial sensitivity of each species.

title: Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of XXXX .

answer: @entity3


abstract: 1. Up to 200 protein staining spots could be detected on two-dimensional electrophoresis of urine from healthy @entity0 . Other minor spots were occasionally present. 2. Although the electropherograms exhibited constant characteristic features some variation in protein pattern was observed between individuals and with a given individual at different times. 3. Two additional proteins, spots C and D, were consistently present in urine from @entity0 with @entity2 . Spot C was also present in the urine of about 60% of obligatory carriers of this @entity3 . 4. The protein responsible for spot C had a molecular weight of 26000 and an isoelectric point of 5.3. 5. Spot C was also detected in the urine of @entity0 with other neuromuscular conditions. Neither spot C nor spot D could be detected in the urine of @entity0 with physical disabilities other than those of neuromuscular origin. 6. It is concluded that the urinary excretion of spot C, and probably of spot D, is a consequence of @entity1 and that their detection has potential as a diagnostic tool.

title: Proteins in the urine associated with XXXX and other neuromuscular diseases.

answer: @entity2


abstract: @entity1 represents one of the major health challenges in modern times and is the number one cause of @entity2 globally. Thus, numerous studies are under way to identify effective cell- and/or @entity4 ( @entity4 )-based therapies for repairing damaged cardiac tissue. In this regard, improving the engraftment or survival of regenerative cells and prolonging @entity4 exposure have become fundamental goals in advancing these therapeutic approaches. Biomaterials have emerged as innovative scaffolds for the delivery of both cells and proteins in tissue engineering applications. In the present study, electrospinning was used to generate smooth homogenous polymeric fibers, which consisted of a poly(lactic-co-glycolic acid) (PLGA)/NCO-sP(EO-stat-PO) polymer blend encapsulating the cardioactive @entity4 , @entity5 ( @entity5 ). We evaluated the biocompatibility and degradation of this @entity5 -containing biomaterial in a @entity0 model of @entity3 . Histological analysis revealed the presence of an initial acute inflammatory response after implantation, which was followed by a chronic inflammatory phase, characterized by the presence of giant cells. Notably, the scaffold remained in the heart after 3 months. Furthermore, an increase in the M2:M1 macrophage ratio following implantation suggested the induction of constructive tissue remodeling. Taken together, the combination of @entity5 -encapsulating scaffolds with cells capable of inducing cardiac regeneration could represent an ambitious and promising therapeutic strategy for repairing diseased or damaged myocardial tissue.

title: Polymeric electrospun scaffolds: neuregulin encapsulation and biocompatibility studies in a model of XXXX .

answer: @entity3


abstract: UNASSIGNED: Direct addition of powdered activated @entity1 (PAC) to a deep-bed filter was investigated at pilot-scale as a single advanced treatment stage for simultaneous removal of organic micropollutants (OMPs) and @entity3 from secondary effluent. PAC doses of 10-50  mg/L were assessed with regard to their impacts on filter performance and removal of 15 selected OMPs over a period of 18 months. The PAC was effectively retained by the filter and had no negative effect on filter head loss. Filter runtime until particle breakthrough depended mainly on coagulant dose and did not decrease significantly due to the additional PAC load. Removal of suspended solids and @entity3 by coagulation was effective independent of the PAC dose. A PAC dose of 35  mg/L PAC was suitable to remove well-adsorbing OMPs (e.g. @entity2 , @entity4 ) by >80% and medium adsorbing OMPs (e.g. @entity5 , @entity0 ) by 50-80%. Median removals were 50-80% for well-adsorbing and 30-50% for medium adsorbing OMPs with 20  mg/L PAC. Abatement of all OMPs was low (<50%) with 10  mg/L PAC, possibly because of the high effluent organic matter content (median dissolved organic @entity1 (DOC) concentrations of 11.2  mg/L). In addition to adsorptive removal, relevant concentration decreases of certain OMPs (e.g. @entity6 ) were attributed to biological transformation in the filter. Adsorption onto accumulating PAC in the top layer of the filter bed led to improved @entity7 adsorption with increasing filter runtime. The comparison of @entity7 removal in the pilot filter with laboratory adsorption tests demonstrates that batch test results can be applied to estimate adsorptive @entity7 removal in real applications.

title: Integrating organic micropollutant removal into tertiary filtration: Combining PAC adsorption with advanced XXXX removal.

answer: @entity3


abstract: UNASSIGNED: This study documents the @entity3 in medication use in @entity0 with refractory chronic @entity2 utilizing a protocol of pelvic floor myofascial trigger point release with an FDA approved internal trigger point wand and paradoxical relaxation therapy. Self-referred @entity0 were enrolled in a 6-day training clinic from October, 2008 to May, 2011 and followed the protocol for 6  months. Medication usage and symptom scores on a 1-10 scale (10  =  most severe) were collected at baseline, @entity1  months. All changes in medication use were at the @entity0 's discretion. Changes in medication use were assessed by McNemar's test in both complete case and modified intention to treat (mITT) analyses. 374 out of 396 @entity0 met inclusion criteria; 79.7  % were male, median age of 43  years and median symptom duration of 5  years. In the complete case analysis, the percent of @entity0 using medications at baseline was 63.6  %. After 6  months of treatment the percentage was 40.1  %, a 36.9  % reduction (p  <  0.001). In the mITT analysis, there was a 22.7  % overall reduction from baseline (p  <  0.001). Medication cessation at 6  months was significantly associated with a reduction in total symptoms (p  =  0.03).

title: Chronic XXXX : Reduction of Medication Use After Pelvic Floor Physical Therapy with an Internal Myofascial Trigger Point Wand.

answer: @entity2


abstract: INTRODUCTION: Spontaneous resolution of @entity3 is a phenomenon that has been described in literature in the past. At present it is not routine practise to scan @entity0 prior to carotid endarterectomy surgery within the UK. PRESENTATION OF CASE: A 58 year old female presented to hospital with a history of sudden onset @entity1 and @entity2 . CT head showed findings in keeping with an acute right MCA territory @entity5 . A duplex ultrasound scan showed echolucent material in the right internal carotid artery forming a greater than 95% @entity4 . The scan was unable to visualise the patency of the vessel distally due to the position of the mandible. The @entity0 was provisionally listed for carotid endarterectomy. An MRA was requested prior to surgery to assess the patency of the distal internal carotid artery. The MRA of the carotids showed normal appearance of the common carotid, internal and vertebral arteries with no definite @entity4 . A repeat duplex ultrasound confirmed there was no significant @entity4 . DISCUSSION: The finding of complete resolution of @entity4 on MRA was an unexpected event. Had the initial duplex imaging allowed visualisation of the distal vessel patency, our @entity0 would have undergone unnecessary carotid surgery with the associated morbidity and mortality. CONCLUSION: This case report draws attention to the benefits of selective preoperative scanning, in sparing @entity0 from unnecessary surgery as a result of finding occlusion or resolution of a previously diagnosed @entity3 .

title: Resolution of XXXX pre-carotid intervention: A case for selective preoperative duplex ultrasound.

answer: @entity3


abstract: UNASSIGNED: We investigated whether disclosure of @entity1 ( @entity1 ) genetic risk influences @entity2 ( @entity2 ) and genetic counseling satisfaction (GCS). @entity0 (n   =   207, age: 45-65   years) were randomized to receive estimated 10-year risk of @entity1 based on a @entity3 ( @entity3 ) with or without a genetic risk score (GRS). Risk estimates were disclosed by a genetic counselor who also reviewed how GRS altered risk in those randomized to @entity3 +GRS. Each @entity0 subsequently met with a physician and then completed surveys to assess @entity2 and GCS. @entity0 who received @entity3 +GRS had higher @entity2 than those who received @entity3 alone although the absolute difference was small (25.2        2.7 vs 24.1        3.8, p   =   0.04). A greater proportion of @entity3 +GRS @entity0 had higher GCS scores (17.3        5.3 vs 15.9        6.3, p   =   0.06). In the @entity3 +GRS group, @entity2 and GCS scores were not correlated with GRS. Within both groups, @entity2 and GCS scores were similar in @entity0 with or without family history (p   =   NS). In conclusion, @entity0 who received their genetic risk of @entity1 had higher @entity2 and tended to have higher GCS. Our findings suggest that disclosure of genetic risk of @entity1 together with conventional risk estimates is appreciated by @entity0 . Whether this results in improved outcomes needs additional investigation.

title: Disclosing genetic risk for XXXX : effects on @entity2 and genetic counseling satisfaction.

answer: @entity1


abstract: UNASSIGNED: We investigated whether disclosure of @entity1 ( @entity1 ) genetic risk influences @entity2 ( @entity2 ) and genetic counseling satisfaction (GCS). @entity0 (n   =   207, age: 45-65   years) were randomized to receive estimated 10-year risk of @entity1 based on a @entity3 ( @entity3 ) with or without a genetic risk score (GRS). Risk estimates were disclosed by a genetic counselor who also reviewed how GRS altered risk in those randomized to @entity3 +GRS. Each @entity0 subsequently met with a physician and then completed surveys to assess @entity2 and GCS. @entity0 who received @entity3 +GRS had higher @entity2 than those who received @entity3 alone although the absolute difference was small (25.2        2.7 vs 24.1        3.8, p   =   0.04). A greater proportion of @entity3 +GRS @entity0 had higher GCS scores (17.3        5.3 vs 15.9        6.3, p   =   0.06). In the @entity3 +GRS group, @entity2 and GCS scores were not correlated with GRS. Within both groups, @entity2 and GCS scores were similar in @entity0 with or without family history (p   =   NS). In conclusion, @entity0 who received their genetic risk of @entity1 had higher @entity2 and tended to have higher GCS. Our findings suggest that disclosure of genetic risk of @entity1 together with conventional risk estimates is appreciated by @entity0 . Whether this results in improved outcomes needs additional investigation.

title: Disclosing genetic risk for @entity1 : effects on XXXX and genetic counseling satisfaction.

answer: @entity2


abstract: OBJECTIVE: To determine the time course of @entity7 and the link with macrovascular endothelial function and circulating markers of endothelial activation in @entity9 ( @entity9 ) in @entity1 . METHODS: Microvascular function/structure and mechanics were studied in third-order mesenteric arteries subjected to flow and/or pressure on day 4 (preclinical @entity6 ), day 11 ( @entity6 ), day 33 (severe disease), and day 90 (when @entity0 has resolved) after @entity9 induction. Macrovascular function was studied in aortic rings, and blood pressure, plasma levels of @entity10 ( @entity10 ), @entity8 ( @entity8 ), and @entity3 ( @entity3 ) were measured at each time point. RESULTS: Mesenteric flow-mediated vasodilation was significantly reduced from @entity6 to @entity2 , whereas increased microvascular arterial stiffness was evident only on day 33. @entity5 was observed only on day 33. Thus, on day 90, whereas @entity1 with @entity9 recovered normal macrovascular endothelial function, microvascular endothelial function remained impaired. No correlation was found between micro- and macrovascular endothelial function throughout the course of @entity6 (r = 0.180, P = 0.229). Furthermore, no correlation was found between @entity10 levels, @entity8 levels, and endothelial function whatever the vascular bed. @entity9 was not associated with change in blood pressure or VCAM levels. CONCLUSION: Our findings indicate that microvascular @entity5 occurs earlier than macrovascular @entity5 and microvascular arterial stiffness during @entity6 , suggesting that microvascular endothelial function would be a valuable tool for the early assessment of cardiovascular risk in @entity4 . Neither the @entity8 level nor the @entity10 level is a good marker of micro- or macrovascular @entity5 .

title: XXXX in @entity9 : relationship to macrovascular endothelial function and markers of endothelial activation.

answer: @entity7


abstract: OBJECTIVE: To determine the time course of @entity7 and the link with macrovascular endothelial function and circulating markers of endothelial activation in @entity9 ( @entity9 ) in @entity1 . METHODS: Microvascular function/structure and mechanics were studied in third-order mesenteric arteries subjected to flow and/or pressure on day 4 (preclinical @entity6 ), day 11 ( @entity6 ), day 33 (severe disease), and day 90 (when @entity0 has resolved) after @entity9 induction. Macrovascular function was studied in aortic rings, and blood pressure, plasma levels of @entity10 ( @entity10 ), @entity8 ( @entity8 ), and @entity3 ( @entity3 ) were measured at each time point. RESULTS: Mesenteric flow-mediated vasodilation was significantly reduced from @entity6 to @entity2 , whereas increased microvascular arterial stiffness was evident only on day 33. @entity5 was observed only on day 33. Thus, on day 90, whereas @entity1 with @entity9 recovered normal macrovascular endothelial function, microvascular endothelial function remained impaired. No correlation was found between micro- and macrovascular endothelial function throughout the course of @entity6 (r = 0.180, P = 0.229). Furthermore, no correlation was found between @entity10 levels, @entity8 levels, and endothelial function whatever the vascular bed. @entity9 was not associated with change in blood pressure or VCAM levels. CONCLUSION: Our findings indicate that microvascular @entity5 occurs earlier than macrovascular @entity5 and microvascular arterial stiffness during @entity6 , suggesting that microvascular endothelial function would be a valuable tool for the early assessment of cardiovascular risk in @entity4 . Neither the @entity8 level nor the @entity10 level is a good marker of micro- or macrovascular @entity5 .

title: @entity7 in XXXX : relationship to macrovascular endothelial function and markers of endothelial activation.

answer: @entity9


abstract: PURPOSE: To retrospectively determine whether the application of thermal ablation to recurrent and advanced @entity3 ( @entity3 ) could allow for @entity1 control. MATERIALS AND METHODS: From 2002 to 2014, 22 @entity0 (17 @entity0 and 5 @entity0 ; mean age, 64 y; age range, 42-88 y) with unresectable @entity3 lesions treated with thermal ablation were evaluated. @entity0 were followed at 3 and 6 months after treatment, every 6 months for 5 years, and yearly thereafter with computed tomography and/or magnetic resonance imaging. The mean follow-up period was 32.2 months (range, 3-51 mo). RESULTS: Three of 22 @entity0 with @entity2 are still alive; two of these @entity0 were treated with radiofrequency (RF) ablation and one was treated with microwave (MW) ablation. Of the 19 remaining @entity0 , four were treated with MW ablation and 15 were treated with RF ablation. Imaging revealed partial response in eight @entity0 , and complete response was observed in the remaining 14. There were two major complications after ablation treatment. The mean survival time was 32.9 months    3.205 (standard error; 95% confidence interval [CI], 26.6-39.2 mo). The survival time for MW ablation cases (36 mo    5.185; 95% CI, 25.8-46.16 mo) was longer than for RF ablation (32.2 mo    3.911; 95% CI, 24.5-39.8 mo), although the CI overlap between the groups is large. CONCLUSIONS: Percutaneous thermal ablation is a promising alternative treatment for local control of incurable @entity3 .

title: Preliminary Results in Unresectable XXXX Treated by Radiofrequency and Microwave Ablation: Feasibility, Efficacy, and Safety.

answer: @entity3


abstract: UNASSIGNED: The rapid development of high-volume horizontal hydraulic fracturing for mining natural gas from shale has posed potential impacts on @entity0 health and biodiversity. The produced flow back waters after hydraulic stimulation are known to carry high levels of saline and total dissolved solids. To understand the @entity1 and potential carcinogenic effects of these wastewaters, flow back waters from five Marcellus hydraulic fracturing oil and gas wells were analyzed. The physicochemical nature of these samples was analyzed by inductively coupled plasma mass spectrometry and scanning electron microscopy/energy dispersive X-ray spectroscopy. A @entity1 study using colony formation as the endpoint was carried out to define the LC50 values of test samples using @entity0 bronchial epithelial cells (BEAS-2B). The BEAS-2B cell transformation assay was employed to assess the carcinogenic potential of the samples. Barium and @entity2 were among the most abundant metals in these samples and the same metals were found to be elevated in BEAS-2B cells after long-term treatment. BEAS-2B cells treated for 6weeks with flow back waters produced colony formation in soft agar that was concentration dependent. In addition, flow back water-transformed BEAS-2B cells show better migration capability when compared to control cells. This study provides information needed to assess the potential health impact of post-hydraulic fracturing flow back waters from Marcellus Shale natural gas mining.

title: Malignant XXXX cell transformation of Marcellus Shale gas drilling flow back water.

answer: @entity0


abstract: Habitat loss, @entity1 and urban expansion may drive some species to marginal habitats while others succeed in exploiting urban areas. Species that show dietary flexibility are more able to take advantage of @entity0 activities to supplement their diet with anthropogenically abundant and accessible resources. The @entity2 ( @entity2 ) is an endangered species due to the loss of its habitat, and @entity0 pressure. The population of Gouraya National Park (Algeria) lives in a relictual habitat that constitutes about 0.6% of the species range. In addition, this population is a unique case where urban expansion favours contact zones between @entity2 habitats and a big city (Bejaia). We quantified the dietary composition of Gouraya macaques over an annual cycle with the objective to understand how diet flexibility of this species may help it adapt to a relictual habitat or cope with urban expansion. We recorded the phenology of plant species every month. This study shows that Gouraya macaques, compared to those living in other forest types of the distribution area, are under lower seasonal constraints. They consume a greater amount of fruit and seeds that are available throughout much of the year, and a lesser amount of costly to find and extract subterranean foods. Therefore the Gouraya relictual habitat appears as a favourable environment compared to other major habitats of that species. This study also shows that colonizing peri-urban zones increases the availability and species richness of diet resources for @entity2 as they consume more @entity0 foods and exotic plants than in farther sites. Adult males eat more @entity0 foods than adult females and immatures do. The exploitation of high-energy anthropogenic food could favour macaque population growth and expansion towards the city center associated with @entity0 /macaque conflicts. We recommend applying management actions to restore macaques back to their natural habitat.

title: Is Diet Flexibility an Adaptive Life Trait for Relictual and Peri-Urban Populations of the Endangered Primate XXXX ?

answer: @entity2


abstract: UNASSIGNED: @entity5 ( @entity8 ) acts through nicotinic and muscarinic @entity8 receptors in the ventral midbrain and striatal areas to influence @entity6 (DA) transmission. This cholinergic control of DA transmission is important for processes such as attention and motivated behavior, and is manipulated by @entity7 in @entity4 products. Identifying and characterizing the key @entity8 receptors involved in cholinergic control of DA transmission could lead to small molecule therapeutics for treating disorders involving @entity1 , @entity3 , and @entity2 . a6-Containing nicotinic @entity5 receptors (nAChRs) are highly and specifically expressed in midbrain DA neurons, making them an attractive drug target. Here, we used genetic, pharmacological, behavioral, and biophysical approaches to study this @entity9 subtype. For many experiments, we used @entity0 expressing mutant a6 nAChRs ("a6L9S" @entity0 ) that increase the sensitivity of these receptors to agonists such as @entity8 and @entity7 . Taking advantage of a simple behavioral phenotype exhibited by a6L9S @entity0 , we compared the ability of full versus partial a6(   ) @entity9 agonists to activate a6(   ) nAChRs in vivo. Using local infusions of both agonists and antagonists into the brain, we demonstrate that neurons and nAChRs in the midbrain are sufficient to account for this behavioral response. To complement these behavioral studies, we studied the ability of in vivo a6(   ) @entity9 activation to support plasticity changes in midbrain DA neurons that are relevant to behavioral sensitization and addiction. By coupling local infusion of drugs and brain slice patch-clamp electrophysiology, we show that activating a6(   ) nAChRs in midbrain DA areas is sufficient to enhance glutamatergic transmission in ventral tegmental area (VTA) DA neurons. Together, these results from in vivo studies strongly suggest that a6(   ) nAChRs expressed by VTA DA neurons are positioned to strongly influence both DA-mediated behaviors and the induction of synaptic plasticity by @entity7 .

title: a6-Containing nicotinic @entity5 receptors in midbrain XXXX neurons are poised to govern @entity6 -mediated behaviors and synaptic plasticity.

answer: @entity6


abstract: UNASSIGNED: @entity5 ( @entity8 ) acts through nicotinic and muscarinic @entity8 receptors in the ventral midbrain and striatal areas to influence @entity6 (DA) transmission. This cholinergic control of DA transmission is important for processes such as attention and motivated behavior, and is manipulated by @entity7 in @entity4 products. Identifying and characterizing the key @entity8 receptors involved in cholinergic control of DA transmission could lead to small molecule therapeutics for treating disorders involving @entity1 , @entity3 , and @entity2 . a6-Containing nicotinic @entity5 receptors (nAChRs) are highly and specifically expressed in midbrain DA neurons, making them an attractive drug target. Here, we used genetic, pharmacological, behavioral, and biophysical approaches to study this @entity9 subtype. For many experiments, we used @entity0 expressing mutant a6 nAChRs ("a6L9S" @entity0 ) that increase the sensitivity of these receptors to agonists such as @entity8 and @entity7 . Taking advantage of a simple behavioral phenotype exhibited by a6L9S @entity0 , we compared the ability of full versus partial a6(   ) @entity9 agonists to activate a6(   ) nAChRs in vivo. Using local infusions of both agonists and antagonists into the brain, we demonstrate that neurons and nAChRs in the midbrain are sufficient to account for this behavioral response. To complement these behavioral studies, we studied the ability of in vivo a6(   ) @entity9 activation to support plasticity changes in midbrain DA neurons that are relevant to behavioral sensitization and addiction. By coupling local infusion of drugs and brain slice patch-clamp electrophysiology, we show that activating a6(   ) nAChRs in midbrain DA areas is sufficient to enhance glutamatergic transmission in ventral tegmental area (VTA) DA neurons. Together, these results from in vivo studies strongly suggest that a6(   ) nAChRs expressed by VTA DA neurons are positioned to strongly influence both DA-mediated behaviors and the induction of synaptic plasticity by @entity7 .

title: a6-Containing nicotinic @entity5 receptors in midbrain @entity6 neurons are poised to govern XXXX -mediated behaviors and synaptic plasticity.

answer: @entity6


abstract: UNASSIGNED: @entity5 ( @entity8 ) acts through nicotinic and muscarinic @entity8 receptors in the ventral midbrain and striatal areas to influence @entity6 (DA) transmission. This cholinergic control of DA transmission is important for processes such as attention and motivated behavior, and is manipulated by @entity7 in @entity4 products. Identifying and characterizing the key @entity8 receptors involved in cholinergic control of DA transmission could lead to small molecule therapeutics for treating disorders involving @entity1 , @entity3 , and @entity2 . a6-Containing nicotinic @entity5 receptors (nAChRs) are highly and specifically expressed in midbrain DA neurons, making them an attractive drug target. Here, we used genetic, pharmacological, behavioral, and biophysical approaches to study this @entity9 subtype. For many experiments, we used @entity0 expressing mutant a6 nAChRs ("a6L9S" @entity0 ) that increase the sensitivity of these receptors to agonists such as @entity8 and @entity7 . Taking advantage of a simple behavioral phenotype exhibited by a6L9S @entity0 , we compared the ability of full versus partial a6(   ) @entity9 agonists to activate a6(   ) nAChRs in vivo. Using local infusions of both agonists and antagonists into the brain, we demonstrate that neurons and nAChRs in the midbrain are sufficient to account for this behavioral response. To complement these behavioral studies, we studied the ability of in vivo a6(   ) @entity9 activation to support plasticity changes in midbrain DA neurons that are relevant to behavioral sensitization and addiction. By coupling local infusion of drugs and brain slice patch-clamp electrophysiology, we show that activating a6(   ) nAChRs in midbrain DA areas is sufficient to enhance glutamatergic transmission in ventral tegmental area (VTA) DA neurons. Together, these results from in vivo studies strongly suggest that a6(   ) nAChRs expressed by VTA DA neurons are positioned to strongly influence both DA-mediated behaviors and the induction of synaptic plasticity by @entity7 .

title: a6-Containing nicotinic XXXX receptors in midbrain @entity6 neurons are poised to govern @entity6 -mediated behaviors and synaptic plasticity.

answer: @entity5


abstract: UNASSIGNED: Purpose: We evaluated the effects of adjuvant intravitreal bevacizumab injection on the outcomes of @entity3 valve (AGV) implantation in @entity0 with @entity5 ( @entity5 ) through a systematic literature review. Methods: An extensive search of PubMed, EMBASE, and the Cochrane Library was performed in November 2014 for selection of relevant studies. The weighted mean difference of the percentage of intraocular pressure reduction (IOPR%) from baseline to endpoint was used as the primary efficacy estimate, and Mantel-Haenszel odds ratios and 95% confidence intervals (CIs) of the success rate were used as the secondary efficacy estimates. The incidence of adverse events was also documented through a review of the studies. Results: Six studies involving 252 @entity0 (256 eyes) were included in this systematic review. The differences in the means and 95% CIs of the IOPR% of 6 studies showed that adjuvant bevacizumab treatment tended to be more effective than AGV implantation alone. Comparison of the outcomes of AGV implantation only with those of AGV implantation+adjuvant bevacizumab showed a success rate in favor of AGV implantation+adjuvant bevacizumab. The incidence of @entity2 -associated complications such as @entity7 , @entity2 , and @entity2 was lower in association with combination treatment than with AGV implantation only. Combination treatment seemed to be associated with a lower incidence of other adverse effects such as @entity8 , flat chamber, @entity4 /effusion, @entity1 , and @entity6 . Conclusion: AGV implantation with adjuvant bevacizumab was more effective and had a higher success rate than surgery alone for lowering IOP in @entity0 with @entity5 . The combined procedure tended to show a lower incidence of @entity2 -associated complications, such as @entity7 .

title: Beneficial Effects of Adjuvant Intravitreal Bevacizumab Injection on Outcomes of Ahmed XXXX in @entity0 with @entity5 : Systematic Literature Review.

answer: @entity3


abstract: UNASSIGNED: Purpose: We evaluated the effects of adjuvant intravitreal bevacizumab injection on the outcomes of @entity3 valve (AGV) implantation in @entity0 with @entity5 ( @entity5 ) through a systematic literature review. Methods: An extensive search of PubMed, EMBASE, and the Cochrane Library was performed in November 2014 for selection of relevant studies. The weighted mean difference of the percentage of intraocular pressure reduction (IOPR%) from baseline to endpoint was used as the primary efficacy estimate, and Mantel-Haenszel odds ratios and 95% confidence intervals (CIs) of the success rate were used as the secondary efficacy estimates. The incidence of adverse events was also documented through a review of the studies. Results: Six studies involving 252 @entity0 (256 eyes) were included in this systematic review. The differences in the means and 95% CIs of the IOPR% of 6 studies showed that adjuvant bevacizumab treatment tended to be more effective than AGV implantation alone. Comparison of the outcomes of AGV implantation only with those of AGV implantation+adjuvant bevacizumab showed a success rate in favor of AGV implantation+adjuvant bevacizumab. The incidence of @entity2 -associated complications such as @entity7 , @entity2 , and @entity2 was lower in association with combination treatment than with AGV implantation only. Combination treatment seemed to be associated with a lower incidence of other adverse effects such as @entity8 , flat chamber, @entity4 /effusion, @entity1 , and @entity6 . Conclusion: AGV implantation with adjuvant bevacizumab was more effective and had a higher success rate than surgery alone for lowering IOP in @entity0 with @entity5 . The combined procedure tended to show a lower incidence of @entity2 -associated complications, such as @entity7 .

title: Beneficial Effects of Adjuvant Intravitreal Bevacizumab Injection on Outcomes of Ahmed @entity3 in @entity0 with XXXX : Systematic Literature Review.

answer: @entity5


abstract: UNASSIGNED: Purpose: We evaluated the effects of adjuvant intravitreal bevacizumab injection on the outcomes of @entity3 valve (AGV) implantation in @entity0 with @entity5 ( @entity5 ) through a systematic literature review. Methods: An extensive search of PubMed, EMBASE, and the Cochrane Library was performed in November 2014 for selection of relevant studies. The weighted mean difference of the percentage of intraocular pressure reduction (IOPR%) from baseline to endpoint was used as the primary efficacy estimate, and Mantel-Haenszel odds ratios and 95% confidence intervals (CIs) of the success rate were used as the secondary efficacy estimates. The incidence of adverse events was also documented through a review of the studies. Results: Six studies involving 252 @entity0 (256 eyes) were included in this systematic review. The differences in the means and 95% CIs of the IOPR% of 6 studies showed that adjuvant bevacizumab treatment tended to be more effective than AGV implantation alone. Comparison of the outcomes of AGV implantation only with those of AGV implantation+adjuvant bevacizumab showed a success rate in favor of AGV implantation+adjuvant bevacizumab. The incidence of @entity2 -associated complications such as @entity7 , @entity2 , and @entity2 was lower in association with combination treatment than with AGV implantation only. Combination treatment seemed to be associated with a lower incidence of other adverse effects such as @entity8 , flat chamber, @entity4 /effusion, @entity1 , and @entity6 . Conclusion: AGV implantation with adjuvant bevacizumab was more effective and had a higher success rate than surgery alone for lowering IOP in @entity0 with @entity5 . The combined procedure tended to show a lower incidence of @entity2 -associated complications, such as @entity7 .

title: Beneficial Effects of Adjuvant Intravitreal Bevacizumab Injection on Outcomes of Ahmed @entity3 in XXXX with @entity5 : Systematic Literature Review.

answer: @entity0


abstract: The objective of this study was to evaluate effects of dietary @entity2 ( @entity2 ) intake on ileal @entity8 digestibilities and expression of genes for digestive enzymes in growing and finishing @entity4 . In Experiment 1, 18 growing @entity4 (average initial BW = 36.5 kg) were assigned randomly into one of three treatments (n = 6/treatment group) representing normal (18 % @entity2 ), low (15 % @entity2 ), and very low (12 % @entity2 ) protein intake. In Experiment 2, 18 finishing @entity4 (average initial BW = 62.3 kg) were allotted randomly into one of three treatments (n = 6/treatment group), representing normal (16 % @entity2 ), low (13 % @entity2 ) and very low (10 % @entity2 ) protein intake. In both experiments, diets with low and very low @entity2 were supplemented with crystalline @entity7 to achieve equal content of standardized ileal digestible Lys, Met, Thr, and Trp, and were provided to @entity4 ad libitum. Daily feed intake, BW, and feed/gain ratios were determined. At the end of each experiment, all @entity4 were slaughtered to collect pancreas, small-intestine samples, and terminal ileal chymes. Samples were used for determining expression of genes for digestive enzymes and ileal @entity8 digestibilities. Growing @entity4 fed the 12 % @entity2 and 15 % @entity2 diets had lower final body weight (P < 0.01) and ADG (P < 0.0001) when compared with @entity4 fed the 18 % dietary @entity2 diet. Growing @entity4 fed with the 12 % @entity2 diet showed higher digestibilities for @entity2 (P < 0.05), @entity9 (P < 0.05), Lys (P < 0.0001), Met (P < 0.01), @entity5 (P < 0.01), Thr (P < 0.01), Trp (P < 0.05), @entity6 (P < 0.05), @entity0 (P < 0.05), Ala (P < 0.05), @entity5 (P < 0.01), and @entity10 (P < 0.05) than those fed the 18 % @entity2 diet. Finishing @entity4 fed the 16 % @entity2 diet had a higher (P < 0.01) final body weight than those fed the 10 % @entity2 diet. mRNA levels for digestive enzymes ( @entity11 , chymotrypsin B, and dipeptidases-II and III) differed among the three groups of @entity4 (P < 0.05), and no difference was noted in the genes expression between control group and lower @entity2 group. These results indicated that a reduction of dietary @entity2 by a six-percentage value limited the growth performance of growing-finishing @entity4 and that a low-protein diet supplemented with deficient @entity7 could reduce the excretion of @entity3 into the environment without affecting @entity1 .

title: Low-protein diets affect ileal XXXX digestibility and gene expression of digestive enzymes in growing and finishing @entity4 .

answer: @entity8


abstract: The objective of this study was to evaluate effects of dietary @entity2 ( @entity2 ) intake on ileal @entity8 digestibilities and expression of genes for digestive enzymes in growing and finishing @entity4 . In Experiment 1, 18 growing @entity4 (average initial BW = 36.5 kg) were assigned randomly into one of three treatments (n = 6/treatment group) representing normal (18 % @entity2 ), low (15 % @entity2 ), and very low (12 % @entity2 ) protein intake. In Experiment 2, 18 finishing @entity4 (average initial BW = 62.3 kg) were allotted randomly into one of three treatments (n = 6/treatment group), representing normal (16 % @entity2 ), low (13 % @entity2 ) and very low (10 % @entity2 ) protein intake. In both experiments, diets with low and very low @entity2 were supplemented with crystalline @entity7 to achieve equal content of standardized ileal digestible Lys, Met, Thr, and Trp, and were provided to @entity4 ad libitum. Daily feed intake, BW, and feed/gain ratios were determined. At the end of each experiment, all @entity4 were slaughtered to collect pancreas, small-intestine samples, and terminal ileal chymes. Samples were used for determining expression of genes for digestive enzymes and ileal @entity8 digestibilities. Growing @entity4 fed the 12 % @entity2 and 15 % @entity2 diets had lower final body weight (P < 0.01) and ADG (P < 0.0001) when compared with @entity4 fed the 18 % dietary @entity2 diet. Growing @entity4 fed with the 12 % @entity2 diet showed higher digestibilities for @entity2 (P < 0.05), @entity9 (P < 0.05), Lys (P < 0.0001), Met (P < 0.01), @entity5 (P < 0.01), Thr (P < 0.01), Trp (P < 0.05), @entity6 (P < 0.05), @entity0 (P < 0.05), Ala (P < 0.05), @entity5 (P < 0.01), and @entity10 (P < 0.05) than those fed the 18 % @entity2 diet. Finishing @entity4 fed the 16 % @entity2 diet had a higher (P < 0.01) final body weight than those fed the 10 % @entity2 diet. mRNA levels for digestive enzymes ( @entity11 , chymotrypsin B, and dipeptidases-II and III) differed among the three groups of @entity4 (P < 0.05), and no difference was noted in the genes expression between control group and lower @entity2 group. These results indicated that a reduction of dietary @entity2 by a six-percentage value limited the growth performance of growing-finishing @entity4 and that a low-protein diet supplemented with deficient @entity7 could reduce the excretion of @entity3 into the environment without affecting @entity1 .

title: Low-protein diets affect ileal @entity8 digestibility and gene expression of digestive enzymes in growing and finishing XXXX .

answer: @entity4


abstract: OBJECTIVE: To determine the association between serum autoantibodies and survival in @entity0 with incident @entity2 ( @entity2 )-pulmonary arterial @entity1 (PAH) enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in @entity3 (PHAROS) Registry. METHODS: @entity0 with definite PAH diagnosed by right heart catheterization within 6 months of registry enrollment were studied. Serum autoantibodies were assayed at each participating institution's clinical laboratory. Mortality data were collected from electronic medical records and/or the Social Security Death Index. Kaplan-Meier survival estimates were reported for five autoantibody groups (anticentromere/AC, nucleolar ANA/ @entity5 , anti-topoisomerase/Scl-70, overlapping or non-specific autoantibodies/other, and a combined group with similar survival consisting of RNA polymerase III, @entity4 , and autoantibody-negative @entity0 ). Cox proportional hazards models permitted examination of the association between autoantibody groups and overall survival, controlling for age, sex, race, and @entity2 disease duration. RESULTS: In all, 162 subjects had PAH, and serum autoantibody and survival information; 60 (37%) had AC, 39 (24%) @entity5 , 11 (7%) Scl-70, 28 (17%) had other, 9 (6%) RNA pol, 8 (5%) @entity4 autoantibodies, and 7 (4%) had negative antibodies; 32 (20%) subjects died over a median follow-up time of 2.1 years (range: 0.01-6.8); 1- and 3-year survival estimates were, respectively, 94% and 78% for AC, 94% and 72% for @entity5 , 89% and 63% for Scl-70, 92% and 79% for the other group, and 100% and 93% for the combined group. Unadjusted and adjusted hazard ratios revealed no statistically significant association between risk of death and autoantibodies. CONCLUSION: Anticentromere and @entity5 autoantibodies are prevalent in @entity2 -PAH @entity0 . An association between serum autoantibodies and survival in @entity0 with @entity2 -PAH was not identified in the PHAROS cohort.

title: Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in XXXX (PHAROS) Registry.

answer: @entity3


abstract: PURPOSE: To compare dynamic and static tibial translation, in @entity0 with anterior cruciate @entity3 , at 2- to 5-year follow-up, with the tibial translation after 4  months of rehabilitation initiated early after the injury. Secondarily, to compare tibial translation in the injured knee and non-injured knee and explore correlations between dynamic and static tibial translation. METHODS: Twelve @entity0 with ACL @entity2 were assessed at 3-8  weeks after @entity1 , after 4  months of structured rehabilitation, and 2-5  years after @entity1 . Sagittal tibial translation was measured during the Lachman test (static translation) and during gait (dynamic translation) using a CA-4000 electrogoniometer. RESULTS: Static tibial translation was increased bilateral 2-5  years after @entity1 , whereas the dynamic tibial translation was unchanged. Tibial translation was greater in the injured knee compared with the non-injured knee (Lachman test 134  N 9.1      1.0 vs. 7.0      1.7  mm, P  =  0.001, gait 5.6      2.1 vs. 4.7      1.8  mm, P  =  0.011). There were no correlations between dynamic and static tibial translation. CONCLUSION: Dynamic tibial translation was unchanged in spite of increased static tibial translation in the ACL-deficient knee at 2- to 5-year follow-up compared to directly after rehabilitation. Dynamic tibial translation did not correlate with the static tibial translation. A more normal gait kinematics may be maintained from completion of a rehabilitation programme to mid-term follow-up in @entity0 with @entity3 treated with rehabilitation only. LEVEL OF EVIDENCE: IV.

title: Dynamic and static tibial translation in @entity0 with anterior cruciate XXXX initially treated with a structured rehabilitation protocol.

answer: @entity3


abstract: PURPOSE: To compare dynamic and static tibial translation, in @entity0 with anterior cruciate @entity3 , at 2- to 5-year follow-up, with the tibial translation after 4  months of rehabilitation initiated early after the injury. Secondarily, to compare tibial translation in the injured knee and non-injured knee and explore correlations between dynamic and static tibial translation. METHODS: Twelve @entity0 with ACL @entity2 were assessed at 3-8  weeks after @entity1 , after 4  months of structured rehabilitation, and 2-5  years after @entity1 . Sagittal tibial translation was measured during the Lachman test (static translation) and during gait (dynamic translation) using a CA-4000 electrogoniometer. RESULTS: Static tibial translation was increased bilateral 2-5  years after @entity1 , whereas the dynamic tibial translation was unchanged. Tibial translation was greater in the injured knee compared with the non-injured knee (Lachman test 134  N 9.1      1.0 vs. 7.0      1.7  mm, P  =  0.001, gait 5.6      2.1 vs. 4.7      1.8  mm, P  =  0.011). There were no correlations between dynamic and static tibial translation. CONCLUSION: Dynamic tibial translation was unchanged in spite of increased static tibial translation in the ACL-deficient knee at 2- to 5-year follow-up compared to directly after rehabilitation. Dynamic tibial translation did not correlate with the static tibial translation. A more normal gait kinematics may be maintained from completion of a rehabilitation programme to mid-term follow-up in @entity0 with @entity3 treated with rehabilitation only. LEVEL OF EVIDENCE: IV.

title: Dynamic and static tibial translation in XXXX with anterior cruciate @entity3 initially treated with a structured rehabilitation protocol.

answer: @entity0


abstract: AIM: This study aimed to investigate the clinicopathological predictors of survival in @entity0 with @entity4 , mass-forming type (ICC-MF), following curative intent hepatectomy. METHODS: Clinical characteristics and outcomes were analyzed in a series of 42 @entity0 who underwent curative hepatectomy for ICC-MF between February 1987 and December 2012. The relationship between immunohistochemical expression profiles of @entity5 ( @entity5 ) core proteins ( @entity7 , @entity6 , and @entity8 ) and surgical outcomes was examined. RESULTS: The overall median follow-up period was 2.6 years (0.2-17.9). Bile duct reconstruction (p  =  0.017), lymph node @entity1 (p  =  0.049), maximal mass diameter >= 5.0  cm (p  =  0.002), and @entity6 expression (p  =  0.003) were identified as significant adverse predictors of overall survival by univariate analysis. Bile duct reconstruction (p  =  0.048), maximal mass diameter  >= 5.0  cm (p  =  0.002), and @entity6 expression (p  =  0.005) were found to be independent predictors of poor prognosis by multivariate analysis. Maximal mass diameter >= 5.0  cm (p  =  0.011) was found to be an independent predictor for the @entity2 recurrence. There was a strong correlation between @entity6 expression and lymph node @entity1 (p  =  0.021). @entity8 expression was more frequent in @entity0 with concurrent @entity6 expression (p  =  0.019). CONCLUSIONS: @entity6 expression was significantly related to long-term prognosis and @entity3 development, and may be a useful prognostic marker.

title: Prognostic evaluation of @entity5 -5AC expression in XXXX , mass-forming type, following hepatectomy.

answer: @entity4


abstract: AIM: This study aimed to investigate the clinicopathological predictors of survival in @entity0 with @entity4 , mass-forming type (ICC-MF), following curative intent hepatectomy. METHODS: Clinical characteristics and outcomes were analyzed in a series of 42 @entity0 who underwent curative hepatectomy for ICC-MF between February 1987 and December 2012. The relationship between immunohistochemical expression profiles of @entity5 ( @entity5 ) core proteins ( @entity7 , @entity6 , and @entity8 ) and surgical outcomes was examined. RESULTS: The overall median follow-up period was 2.6 years (0.2-17.9). Bile duct reconstruction (p  =  0.017), lymph node @entity1 (p  =  0.049), maximal mass diameter >= 5.0  cm (p  =  0.002), and @entity6 expression (p  =  0.003) were identified as significant adverse predictors of overall survival by univariate analysis. Bile duct reconstruction (p  =  0.048), maximal mass diameter  >= 5.0  cm (p  =  0.002), and @entity6 expression (p  =  0.005) were found to be independent predictors of poor prognosis by multivariate analysis. Maximal mass diameter >= 5.0  cm (p  =  0.011) was found to be an independent predictor for the @entity2 recurrence. There was a strong correlation between @entity6 expression and lymph node @entity1 (p  =  0.021). @entity8 expression was more frequent in @entity0 with concurrent @entity6 expression (p  =  0.019). CONCLUSIONS: @entity6 expression was significantly related to long-term prognosis and @entity3 development, and may be a useful prognostic marker.

title: Prognostic evaluation of XXXX -5AC expression in @entity4 , mass-forming type, following hepatectomy.

answer: @entity5


abstract: UNASSIGNED: Although @entity2 is famous for its reactive @entity0 species (ROS) scavenging function and plays a protective role in biotic stress, its regulatory function in abiotic stress still remains to be elucidated. Our previous study showed that exogenously applied @entity2 ( @entity5 ) could improve abiotic stress tolerance in @entity1 . Here, we report that endogenously increased @entity5 also conferred tolerance to drought and salt stress in @entity1 . Moreover, both exogenous and endogenous @entity5 delayed senescence and flowering time. Polysomal profiling results showed that global translation was enhanced after @entity5 treatment and by the induced-increase of @entity5 level by salt stress. By performing transcriptomic analyses of steady-state and polysome-bound mRNAs in @entity5 -treated plants, we reveal that @entity5 has a substantial impact on translation. Translational changes induced by @entity5 treatment target numerous hormones and stress signaling molecules, which might contribute to the enhanced stress tolerance in @entity5 -treated plants. Our translatome analysis also revealed that @entity3 ( @entity4 ), auxin and @entity6 (JA) biosynthesis as well as signaling genes were activated during @entity5 treatment, which has not been reported in previously published transcriptomic data. Together, our data suggest that the increased @entity2 level results in stress tolerance and global translational changes. This article is protected by copyright. All rights reserved.

title: Increased XXXX contributes to stress tolerance and global translational changes in @entity1 .

answer: @entity2


abstract: UNASSIGNED: Although @entity2 is famous for its reactive @entity0 species (ROS) scavenging function and plays a protective role in biotic stress, its regulatory function in abiotic stress still remains to be elucidated. Our previous study showed that exogenously applied @entity2 ( @entity5 ) could improve abiotic stress tolerance in @entity1 . Here, we report that endogenously increased @entity5 also conferred tolerance to drought and salt stress in @entity1 . Moreover, both exogenous and endogenous @entity5 delayed senescence and flowering time. Polysomal profiling results showed that global translation was enhanced after @entity5 treatment and by the induced-increase of @entity5 level by salt stress. By performing transcriptomic analyses of steady-state and polysome-bound mRNAs in @entity5 -treated plants, we reveal that @entity5 has a substantial impact on translation. Translational changes induced by @entity5 treatment target numerous hormones and stress signaling molecules, which might contribute to the enhanced stress tolerance in @entity5 -treated plants. Our translatome analysis also revealed that @entity3 ( @entity4 ), auxin and @entity6 (JA) biosynthesis as well as signaling genes were activated during @entity5 treatment, which has not been reported in previously published transcriptomic data. Together, our data suggest that the increased @entity2 level results in stress tolerance and global translational changes. This article is protected by copyright. All rights reserved.

title: Increased @entity2 contributes to stress tolerance and global translational changes in XXXX .

answer: @entity1


abstract: The aetiology of @entity7 ranges from food, insect venom, drugs and various chemicals. Some individuals do not develop @entity7 with the offending agent unless ingestion is related temporally to physical exertion, namely food dependent exercise induced @entity7 (FDEIA). The foods implicated are @entity8 , soya, peanut, milk and sea food. A retrospective study on @entity0 with FDEIA from two Allergy clinics in @entity9 Lanka from 2011 to 2015 is reported. @entity0 were selected who fulfilled the following criteria: clinical diagnosis of @entity7 according to the @entity4 ( @entity4 ) criteria, where the onset of symptoms was during exertion, within 4  h of ingesting a food, the ability to eat the implicated food independent of exercise, or exercise safely, if the food was not ingested in the preceding 4  h and an in vitro (ImmunoCap serum IgE to the food) or in vivo (skin prick test) test indicating evidence of sensitivity to the food. There were 19 @entity0 (12 males: 7 females). The ages ranged from 9 to 45 (mean 22.9, median 19  years). Eight @entity0 (42.1%) were in the 9-16 age group. Those below 16  years had a male:female ratio of 3:5, while for those above 16  years it was 9:2. @entity8 was the only food implicated in FDEIA in all @entity0 and was confirmed by skin prick testing, or by ImmunoCap specific IgE to @entity8 or     -  5 gliadin. All @entity0 had @entity1 , while 5/19 (26.3%) had @entity2 of the lips. Fifteen @entity0 (78.9%) had @entity5 of breath or wheezing, while 8 (42.1%) had lost consciousness. Nine @entity0 (47. 3%) had @entity3 . Fourteen (73.6%) of our @entity0 had severe reactions, with @entity6 or @entity3 , while 5 (26.3%) had symptoms related to the gastrointestinal tract. One @entity0 developed @entity7 on two occasions following inhalation of ganja, a local cannabis derivative along with the ingestion of @entity8 and exertion. @entity8 is the main food implicated in FDEIA in @entity9 Lanka. A local cannabis derivative, ganja has been implicated as a cofactor for the first time.

title: Food dependant exercise induced XXXX a retrospective study from 2 @entity4 clinics in Colombo, @entity9 Lanka.

answer: @entity7


abstract: The aetiology of @entity7 ranges from food, insect venom, drugs and various chemicals. Some individuals do not develop @entity7 with the offending agent unless ingestion is related temporally to physical exertion, namely food dependent exercise induced @entity7 (FDEIA). The foods implicated are @entity8 , soya, peanut, milk and sea food. A retrospective study on @entity0 with FDEIA from two Allergy clinics in @entity9 Lanka from 2011 to 2015 is reported. @entity0 were selected who fulfilled the following criteria: clinical diagnosis of @entity7 according to the @entity4 ( @entity4 ) criteria, where the onset of symptoms was during exertion, within 4  h of ingesting a food, the ability to eat the implicated food independent of exercise, or exercise safely, if the food was not ingested in the preceding 4  h and an in vitro (ImmunoCap serum IgE to the food) or in vivo (skin prick test) test indicating evidence of sensitivity to the food. There were 19 @entity0 (12 males: 7 females). The ages ranged from 9 to 45 (mean 22.9, median 19  years). Eight @entity0 (42.1%) were in the 9-16 age group. Those below 16  years had a male:female ratio of 3:5, while for those above 16  years it was 9:2. @entity8 was the only food implicated in FDEIA in all @entity0 and was confirmed by skin prick testing, or by ImmunoCap specific IgE to @entity8 or     -  5 gliadin. All @entity0 had @entity1 , while 5/19 (26.3%) had @entity2 of the lips. Fifteen @entity0 (78.9%) had @entity5 of breath or wheezing, while 8 (42.1%) had lost consciousness. Nine @entity0 (47. 3%) had @entity3 . Fourteen (73.6%) of our @entity0 had severe reactions, with @entity6 or @entity3 , while 5 (26.3%) had symptoms related to the gastrointestinal tract. One @entity0 developed @entity7 on two occasions following inhalation of ganja, a local cannabis derivative along with the ingestion of @entity8 and exertion. @entity8 is the main food implicated in FDEIA in @entity9 Lanka. A local cannabis derivative, ganja has been implicated as a cofactor for the first time.

title: Food dependant exercise induced @entity7 a retrospective study from 2 @entity4 clinics in Colombo, XXXX Lanka.

answer: @entity9